Dopamine D1 receptor availability is not associated with delusional ideation measures of psychosis proneness.


Journal

Schizophrenia research
ISSN: 1573-2509
Titre abrégé: Schizophr Res
Pays: Netherlands
ID NLM: 8804207

Informations de publication

Date de publication:
08 2020
Historique:
received: 28 02 2020
revised: 25 05 2020
accepted: 01 06 2020
pubmed: 4 7 2020
medline: 19 5 2021
entrez: 4 7 2020
Statut: ppublish

Résumé

The dopamine D1 receptor (D1R) is thought to play a role in psychosis and schizophrenia, however positron emission tomography studies comparing patients and controls have been inconsistent. To circumvent some of the limitations of clinical studies, such as antipsychotic exposure, an alternative approach is to examine subclinical psychotic symptoms within the general population, i.e. psychosis proneness traits. In this study, we investigated whether D1R availability is associated with delusional ideation in healthy controls, in four experiments, using [

Identifiants

pubmed: 32616361
pii: S0920-9964(20)30345-5
doi: 10.1016/j.schres.2020.06.001
pii:
doi:

Substances chimiques

Receptors, Dopamine D1 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

175-184

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare no conflicts of interest. SC has received grant support from AstraZeneca as co-investigator, and has served as speaker for Roche and Otsuka Pharmaceuticals. L.F. was, during the study, employed at the Precision Medicine and Genomics, IMED Biotech Unit at Karolinska Institutet.

Auteurs

Granville J Matheson (GJ)

Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, SE-171 76 Stockholm, Sweden. Electronic address: granville.matheson@ki.se.

Pontus Plavén-Sigray (P)

Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, SE-171 76 Stockholm, Sweden.

Anaïs Louzolo (A)

Department of Clinical Neuroscience, Karolinska Institutet, SE-171 76 Stockholm, Sweden.

Jacqueline Borg (J)

Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, SE-171 76 Stockholm, Sweden.

Lars Farde (L)

Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, SE-171 76 Stockholm, Sweden; PET Science Centre, Precision Medicine and Genomics, IMED Biotech Unit, AstraZeneca, Karolinska Institutet, Sweden.

Predrag Petrovic (P)

Department of Clinical Neuroscience, Karolinska Institutet, SE-171 76 Stockholm, Sweden.

Simon Cervenka (S)

Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, SE-171 76 Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH